Herantis Pharma (HRNTS) investor relations material

Market opportunity and unmet need

• Parkinson's disease affects 10–25 million people globally, with a $250 billion economic impact and a projected therapeutic market of $13 billion by 2034.

• Current treatments only address symptoms, not disease progression, and lose effectiveness over time.

• There is strong pharmaceutical interest in disease-modifying therapies for Parkinson's.

Lead asset HER-096: Mechanism and differentiation

• HER-096 is a synthetic peptide mimicking CDNF, designed to protect and restore dopaminergic neurons via the unfolded protein response (UPR) pathway.

• Demonstrates efficient brain penetration and subcutaneous administration, with robust preclinical and Phase 1 data.

• Targets broad neuroprotective and regenerative pathways, differentiating it from competitors focused on narrower mechanisms.

Preclinical and clinical data

• Preclinical studies show HER-096 reduces α-synuclein aggregates, neuroinflammation, and protects dopamine neurons, improving motor symptoms in Parkinson's models.

• Phase 1 trials in healthy volunteers and PD patients demonstrated favorable safety, tolerability, and efficient brain penetration.

• Biomarker analyses in Phase 1b revealed broad modulation of proteostasis, inflammation, and mitochondrial function, aligning with the drug's mechanism.